Haemonetics Q2 FY27 Earnings Beat on Plasma Business Surge as Biopharma R&D Recovery Drives Demand

The Quick Take

• Haemonetics (HAE) beat earnings estimates as its plasma business posted strong growth, capitalising on biopharma R&D recovery and rising plasma-derived medicine demand.
• Strategic guidance was raised following the earnings beat, signalling management confidence in sustained plasma collection volume growth through FY27.
• Two Ariel Capital fund portfolios (Ariel Appreciation and Ariel Small Cap) hold Haemonetics, reflecting institutional conviction in the biopharma demand recovery thesis.

Haemonetics Corporation posted an earnings beat driven by strong growth in its plasma collection business, capitalising on the recovery in biopharma R&D spending and accelerating demand for plasma-derived medicines. Haemonetics' NexSys PCS system — which automates plasma collection and processing for blood collection centres — benefits directly from plasma donation volume growth, which correlates with pharmaceutical company demand for plasma fractionation inputs. The biopharma R&D recovery following a multi-year innovation drought in biologics is accelerating plasma-derived medicine pipeline development, creating sustained downstream demand for Haemonetics' collection equipment and disposables.

The strategic guidance raise following the Q2 beat reflects management's confidence that plasma collection volumes are in a sustained growth phase rather than a cyclical bounce. Plasma donation volumes had recovered from COVID-era lows by 2024 and have continued to grow as collection centre networks expand in the US and Europe. Haemonetics' market position as a leading provider of automated plasma collection technology gives it operational leverage on volume growth — disposable kit revenue scales proportionally with collection volumes, providing high-margin recurring revenue as the installed base grows. Multiple Ariel Capital funds' portfolio positions in Haemonetics reflect institutional conviction that the company is in a multi-year earnings recovery cycle.

The forward watch for Haemonetics investors is plasma collection volume data from major plasma fractionators CSL Behring, Grifols, and Takeda — their collection volume guidance directly drives Haemonetics disposable kit demand 12-18 months forward. Any acceleration in immunoglobulin demand, driven by new therapeutic indications or geographic market expansion in China and Southeast Asia, would provide an additional tailwind. Monitor Haemonetics' gross margin trajectory on its plasma business — NexSys ASP (average selling price) and disposable margins determine whether the revenue growth translates into proportional operating leverage or is accompanied by pricing concessions to plasma centre customers.

Synthesized from 2 sources.